

IFW

PATENT ATTORNEY DOCKET NO. 07891/025005

| Certificate of Mailing: Date of Deposit | t:May 5, 2005 |
|---|---------------|
| I hereby certify under 37 C.F.R. § 1.8(a) that this correspondent Service as first class mail with sufficient postage on the date | O 1 |
| Amendment, Commissioner for Patents, P.O. Box 1450, Alex | <u>-</u> |
| | Promy What |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jeremy Waterman

Robert G. Korneluk et al.

Art Unit:

1635

Serial No.:

10/636,065

Printed name of person mailing correspondence

Examiner:

Not Yet Assigned

rson mailing correspondence

Filed:

August 7, 2003

Customer No.:

21559

Title:

ANTISENSE IAP OLIGONUCLEOTIDES AND USES THEREOF

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully/submitted,

Date: May 2, 2005

Kristina Bieker-Brady, Ph.D

Reg. No. 39,109

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Sheet 1 of 7_

07891/025005 Attorney Docket No. SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Serial No. 10/636,065 Applicant Robert G. Korneluk et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date August 7, 2003 (Use several sheets if necessary) Group 1635 (37 C.F.R. ∋ 1.98(b)) **IDS Filed** May 5, 2005 Customer No. 21559

| | | <u> </u> | J.S. PATENT DOCUMENTS | | | |
|------------------------|--------------------|---------------------------------|-----------------------------|--------------|--|--------------------------------|
| Examiner's Initials | Document Number | Issue or Publication Date | Patentee or Applicant | Class | Subclass | Filing Date (If Appropriate |
| - · | 5,510,239 | 04/23/96 | Baracchini et al. | | | |
| | 5,576,208 | 11/19/96 | Monia et al. | | | |
| | 5,605,022 | 2/25/97 | Fulton | | | |
| | 5,665,550 | 09/09/97 | Roninson et al. | | | |
| | 5,919,912 | 07/06/99 | Korneluk et al. | | | |
| | 5,958,771 | 09/28/99 | Bennett et al. | | | - |
| | 5,958,772 | 09/28/99 | Bennett et al. | | | |
| | 6,087,173 | 07/11/00 | Bennett et al. | | | |
| | 6,107,041 | 08/22/00 | Korneluk et al. | | | |
| | 6,133,437 | 10/17/00 | Korneluk et al. | | | |
| ···· | 6,156,535 | 12/05/00 | Korneluk et al. | | · | |
| . , | 6,187,557 | 02/13/01 | Rothe et al. | | | |
| | 6,300,492 | 10/9/01 | Korneluk et al. | | | |
| · | 6,673,917 | 1/6/2004 | Korneluk et al. | | | |
| 1" | 2002/0168631 | 11/14/02 | Park et al. | | | |
| | FORE | ICN DATENTS OF | PUBLISHED FOREIGN PATENT A | ADDUCATIO | DNC . | |
| . | TORE | -I | T TOOLISHED FOREIGN PATENT | T | 7NS | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
| | WO 94/06814 | 03/31/94 | WIPO | | | |
| | WO 95/19431 | 07/20/95 | WIPO | | | |
| | WO 96/12016 | 04/25/96 | WIPO | | | |

| | 6.4 | INI | _ | _ |
|-----|-----|-----|---|---|
| EXA | IVI | HΝ | ᆮ | г |

DATE CONSIDERED

| | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 07891/025005 |
|-----------------------------------|--|---------------------|---------------------------|
| | | Serial No. | 10/636,065 |
| INFORMATI | ON DISCLOSURE | Applicant | Robert G. Korneluk et al. |
| STATEMEN | T BY APPLICANT | Filing Date | August 7, 2003 |
| (Use several sheets if necessary) | | Group | 1635 |
| (37 C.F.R. ∍ 1.98(b)) | | IDS Filed | May 5, 2005 |
| | | Customer No. | 21559 |

| | WO 97/06182 | 02/20/97 | WIPO | | T | |
|----------|---|---|--|---------------------|-----------------|---------------------------------------|
| | WO 97/06255 | 02/20/97 | WIPO | | | |
| | WO 97/26331 | 07/24/97 | WIPO | | | |
| | WO 98/22131 | 05/28/98 | WIPO | | | · · · · · · · · · · · · · · · · · · · |
| | WO 98/35693 | 08/20/98 | WIPO | | | |
| | WO 00/05366 | 02/03/00 | WIPO | | | |
| | WO 00/32816 | 06/08/00 | WIPO | | | |
| | WO 00/32818 | 06/08/00 | WIPO | | | |
| | WO 00/61595 | 10/19/00 | WIPO | | | |
| | WO 01/18024 | 03/15/01 | WIPO | | | - |
| | WO 02/26968 | 04/04/02 | WIPO | | | |
| | | - | | | <u>-</u> . | |
| | Agrawal et al., "Ar | ntisense Therape | eutics," Curr. Opin. Chem. B. | iol. 2:519-528 (199 | 8). | |
| | (AML): Regulation | Andreeff et al., "Inhibitor-of-apoptosis (IAP) Proteins XIAP and Survivin in Primary Acute Myelogenous Leukemias (AML): Regulation and Therapeutic Targets," Proceedings Annual Meeting of the American Association for Cancer Research, <i>Abstract</i> 41:739-740 (2000). | | | | |
| | | | ibiting Gene From a Nuclea . 68:2521-2528 (1994). | r Polyhedrosis Viru | is Encoding a F | Polypeptide with |
| | Branch, "A Good | Antisense Molec | ule Is Hard To Find," <i>Trends</i> | Biochem. Sci. 23 | : 45-50 (1998). | |
| | Campbell, "Monoclonal Antibody Technology," Elsevier Science, Publishers B.V. New York, NY, (1984). | | | | | |
| | Cheng et al., "Characterisations of Taxol-induced Apoptosis and Altered Gene Expression in Human Breast Cancer Cells," Cellular Pharmacol. 2: 249-257 (1995). | | | | | |
| | Cheng et al., "Sta Neurons in the Ab | Cheng et al., "Staurosporine, K-252a, And K-252b Stabilize Calcium Homeostasis and Promote Survival of CNS Neurons in the Absence of Glucose," <i>J. Neurochem.</i> 62:1319-1329 (1994). | | | | |
| | Chirila et al., "The Use of Synthetic Polymers for Delivery of Therapeutic Antisense Oligodeoxynucleotides," Biomaterials 23: 321-342 (2002). | | | | | |
| <u> </u> | <u> </u> | | | | | |

| EXAM | IINER |
|------|-------|
|------|-------|

DATE CONSIDERED

Sheet 3 of 7_

| SUBSTITUTE FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE | Attorney Docket No. | 07891/025005 |
|--|-----------------------------|---------------------|---------------------------|
| (MODIFIED) PATENT AND TRADEMARK OFFICE | | Serial No. | 10/636,065 |
| INFORMATI | ON DISCLOSURE | Applicant | Robert G. Korneluk et al. |
| STATEMEN | T BY APPLICANT | Filing Date | August 7, 2003 |
| (Use several sheets if necessary) | | Group | 1635 |
| (37 C.F.R. ∍ 1.98(b)) | | IDS Filed | May 5, 2005 |
| | | Customer No. | 21559 |

| ; | Clem et al., "Prevention of Apoptosis by a Baculovirus Gene During Infection of Insect Cells," Science 254:1388-1390 (1991). |
|---|---|
| | Clem et al., "Control of Programmed Cell Death by the Baculovirus Genes p35 And iap," Mol. Cel. Biol. 14:5212-5222 (1994). |
| | Clem et al., "Anti-apoptotic Genes of Baculoviruses," Cell Death and Differentiation 3:9-16 (1996). |
| | Crook et al., "An Apoptosis-inhibiting Baculovirus Gene with a Zinc Finger-like Motif," J. Virol. 67:2168-2174 (1993). |
| | Dhein et al., "Autocrine T-cell Suicide Mediated by APO-1/(Fas/CD95)," Nature 373:438-441 (1995). |
| | Dierlamm et al., "The Apoptosis Inhibitor Gene API2 and a Novel 18q Gene, MLT, Are Recurrently Rearranged in the t(11;18)(q21;q21) Associated with Mucosa-Associated Lymphoid Tissue Lymphomas," <i>Blood</i> 93: 3601-3609 (1999). |
| | Duckett et al., "A Conserved Family of Cellular Genes Related to the Baculovirus IAP Gene and Encoding Apoptosis Inhibitors," <i>EMBO J.</i> 15:2685-2694 (1996). |
| | Erl et al., "Nuclear Factor-kappa B Regulates Induction of Apoptosis and Inhibitor of Apoptosis Protein-1 Expression in Vascular Smooth Muscle Cells," Cir. Res. 84:668-677 (1999). |
| | Fallo et al., "Effects of Taxol on the Human NCI-H295 Adrenocortical Carcinoma Cell Line," <i>Endocr. Res.</i> 22: 709-715 (1996). |
| | Fernandez et al., "Differential Sensitivity of Normal and Ha-ras-transformed C3H Mouse Embryo Fibroblasts to Tumor Necrosis Factor: Induction of bcl-2, c-myc, and Manganese Superoxide Dismutase in Resistant Cells," Oncogene 9:2009-2017 (1994). |
| | Ferrari et al., "N-acetylcysteine (D- and L-stereoisomers) Prevents Apoptotic Death of Neuronal Cells," J. Neurosci. 15:2857-2866 (1995). |
| | Fisher et al., "Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome," Cell 81:935-946 (1995). |
| | Francis et al., "The Response Of GABAergic and Cholinergic Neurons to Transient Cerebral Ischemia," <i>Brain</i> Res. 243:271-278 (1982). |
| | Galderisi et al., "Antisense Oligonucleotides as Therapeutic Agents," J. Cell. Physio. 181: 251-257 (1999). |
| | Gewirtz, "Antisense Oligonucleotide Therapeutics for Human Leukemia," Curr. Opin. Hematol. 5 : 59-71 (1998). |
| | Gibellini et al., "Tat-expressing Jurkat Cells Show an Increased Resistance to Different Apoptotic Stimuli, Including Acute Human Immunodeficiency Virus-type 1 (HIV-1) Infection," <i>Br. J. Haematol.</i> 89:24-33 (1995). |

| EXAMINER | DATE CONSIDERED | | |
|---|--|--|--|
| EXAMINER: Initial citation considered. Draw line through citation | if not in conformance and not considered. Include conv.of this | | |

form with the next communication to applicant.

Sheet_4 of 7_

| SUBSTITUTE FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE | Attorney Docket No. | 07891/025005 |
|-----------------------------------|------------------------------|---------------------|---------------------------|
| (MODIFIED) | PATENT AND TRADEMARK OFFICE | Serial No. | 10/636,065 |
| INFORMATION | ON DISCLOSURE | Applicant | Robert G. Korneluk et al. |
| STATEMEN | ON DISCLOSURE T BY APPLICANT | Filing Date | August 7, 2003 |
| (Use several sheets if necessary) | | Group | 1635 |
| (37 C.F.R. ∍ 1.98(b)) | | IDS Filed | May 5, 2005 |
| | | Customer No. | 21559 |

| | <u>. </u> | |
|----------|---|--|
| | Glicksman et al., "K-252a and Staurosporine Pro Cultures," <i>J. Neurochem.</i> 61:210-221 (1993). | mote Choline Acetyltransferase Activity in Rat Spinal Cord |
| | Glicksman et al., "A K-252a Analog Prevents De Chat Activity in Adult Motoneurons In Vivo," Soc. | velopmentally Programmed Motoneuron Death and the Loss of Neuro. Abst. 441 (1994). |
| | Glicksman et al., "K-252a Promotes Survival and Forebrain Neuronal Cultures," J. Neurochem. 64 | Choline Acetyltransferase Activity in Striatal and Basal :1502-1512 (1995). |
| | Golstein et al., "Homology Between Reaper and (1995). | the Cell Death Domains of Fas and TNFR1," Cell 81:185-186 |
| | Goruppi et al., "Dissection of c-myc Domains Inve 9:1537-1544 (1994). | olved in S Phase Induction of NIH3T3 Fibroblasts," Oncogene |
| | Harrington et al., "c-Myc-induced Apoptosis in Fil 3295 (1994). | problasts is Inhibited by Specific Cytokines," EMBO J. 13:3286- |
| | Holcik, et al. "Translational Upregulaton of X-Link Radiation Induced Cell Death," Oncogene 19:41 | ted Inhibitor of Apoptosis (XIAP) Increases Resistance to 74-4177 (2000). |
| | Holcik et al., "XIAP: Apoptotic Brake and Promisi | ing Therapeutic Target," Apoptosis 6:253-261 (2001). |
| | | XIAP Induce Apoptosis and Enhance Therapeutic Activity ned With Anticancer Drug in Vitro and in Vivo," Proceedings of anual Meeting 43:576 (2002). |
| | Itoh et al., "A Novel Protein Required for Apoptos 268:10932-10937 (1993). | iis. Mutational Analysis of Human Fas Antigen," J. Biol. Chem. |
| | Jansen et al., "Chemosensitisation of malignant (2000). | melanoma by BCL2 antisense therapy," Lancet 356: 1728-1733 |
| | Jansen et al., "Antisense therapy for cancer-the t | ime of truth," Lancet Oncol. 3:672-683 (2002). |
| | Jen et al., "Suppression of Gene Expression by Current Strategies," Stem Cells 18:307-319 (200 | argeted Disruption of Messenger RNA: Available Options and 0). |
| | Jones et al., "Deterin, a New Inhibitor of Apoptos 22165 (2000). | is from Drosophila Melanogaster," J. Biol. Chem. 275 : 22157- |
| | Katsikis et al., "Fas Antigen Stimulation Induces Immunodeficiency Virus-infected Individuals," J. | |
| | Kerr, "Neglected Opportunities in Apoptosis Resu | earch," Trends Cell Biol. 5:55-57 (1995). |
| | Korsmeyer, "Regulators of Cell Death," Trends G | Senet. 11:101-105 (1995). |
| EXAMINER | | DATE CONSIDERED |

| SUBSTITUTE FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE | Attorney Docket No. | 07891/025005 |
|-----------------------------------|--|---------------------|---------------------------|
| (MODIFIED) | (MODIFIED) PATENT AND TRADEMARK OFFICE | | 10/636,065 |
| INITODMATI | ON DIGGLOGUES | Applicant | Robert G. Korneluk et al. |
| STATEMEN | ON DISCLOSURE T BY APPLICANT | Filing Date | August 7, 2003 |
| (Use several sheets if necessary) | | Group | 1635 |
| (37 C.F.R. ∍ 1.98(b)) | | IDS Filed | May 5, 2005 |
| | | Customer No. | 21559 |

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

Sheet 6 of 7

| SUBSTITUTE FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE | Attorney Docket No. | 07891/025005 |
|---|-----------------------------|---------------------|---------------------------|
| (MODIFIED) | PATENT AND TRADEMARK OFFICE | Serial No. | 10/636,065 |
| INCORNATI | INFORMATION DIGGLOCUES | | Robert G. Korneluk et al. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Filing Date | August 7, 2003 |
| | | Group | 1635 |
| (37 C.F.R. ∋ 1.98(b)) | | IDS Filed | May 5, 2005 |
| | | Customer No. | 21559 |

| | Rabizadeh et al., "Expression of the Baculovirus Neurochem. 61:2318-2321 (1993). | p35 Gene Inhibits Mammalian Neural Cell Death," J. |
|---|---|---|
| | Neurocnem. 61:2316-2321 (1993). | |
| | Ridoux et al., "The Use of Adenovirus Vectors for Neuroreport. 5:801-804 (1994). | Intracerebral Grafting of Transfected Nervous Cells," |
| | Ridoux et al., "Adenoviral Vectors as Functional R | Retrograde Neuronal Tracers," Brain Res. 648:171-175 (1994). |
| | Ridoux et al., "Ex Vivo Culture of Adult Microglial 317:217-224 (1994). | Cells from Previously Lesioned Rat Brains," C.R. Acad. Sci. III |
| | Rieux-Laucat et al., "Mutations in Fas Associated Science 268:1347-1349 (1995). | with Human Lymphoproliferative Syndrome and Autoimmunity, |
| | Rosenbaum et al., "Evidence For Hypoxia-induce 36:864-870 (1994). | ed, Programmed Cell Death Of Cultured Neurons," Ann. Neurol. |
| Rothe et al., "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to B of Apoptosis Proteins," <i>Cell</i> 83:1243-1252 (1995). Roy et al., "The Gene for Neuronal Apoptosis Inhibitory Protein is Partially Deleted in Individua Muscular Atrophy," <i>Cell</i> 80:167-178 (1995). | | |
| | | ibitory Protein is Partially Deleted in Individuals with Spinal |
| | Sasaki, et al., "Down-regulation of X-Linked Inhibitor of Apoptosis Protein Induces Apoptosis in Chemoresistant Human Ovarian Cancer Cells," Cancer Res. 60:5659-5666 (2000). | |
| Sato et al., "Neuronal Differentiation Of PC12 Cells as a Result of Prevention of Cell De Neurobiol. 25:1227-1234 (1994). Sauer et al., "Progressive Degeneration of Nigrostriatal Dopamine Neurons Following Ir Lesions with 6-hydroxydopamine: A Combined Retrograde Tracing And Immunocytoche Neurosci. 59:401-415 (1994). | | lls as a Result of Prevention of Cell Death by bcl-2," J. |
| | | |
| | Semba et al., "Organization of Central Cholinergic Systems," Prog. Brain Res. 79:37-63 (1989). | |
| Smith-Swintosky et al., "K252A, K252B and Staurosporine Increase Hippocampal Neuron Survival a Water Maze Performance After Kainate Lesion," Soc. Neuro. Abst. 2130 (1995). Steiman et al., "Infantile Neuronal Degeneration Masquerading as Werdnig-Hoffmann Disease," An 8:317-324 (1980). Stein, "How To Design An Antisense Oligodeoxynucleotide Experiment: A Consensus Approach," A Nucleic Acid Drug Development 8:129-132 (1998). Stein, "Is Irrelevant Cleavage the Price of Antisense Efficacy?" Pharmacol Ther. 85:231-236 (2000) | | |
| | | Masquerading as Werdnig-Hoffmann Disease," Ann. Neurol. |
| | | |
| | | nse Efficacy?" Pharmacol Ther. 85:231-236 (2000). |
| | Steller, "Mechanisms and Genes of Cellular Suic | ide," Science 267:1445-1449 (1995). |
| | | DATE CONSIDERED |

Sheet 7 of 7_

| SUBSTITUTE FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE | Attorney Docket No. | 07891/025005 |
|---|-----------------------------|---------------------|---------------------------|
| (MODIFIED) PATENT AND T | PATENT AND TRADEMARK OFFICE | Serial No. | 10/636,065 |
| INFORMATI | INFORMATION PROGRAMME | | Robert G. Korneluk et al. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Filing Date | August 7, 2003 |
| | | Group | 1635 |
| (37 C.F.R. ∋ 1.98(b)) | | IDS Filed | May 5, 2005 |
| | | Customer No. | 21559 |

| Ta Ai | Talley et al., "Tumor Necrosis Factor Alpha-induced Apoptosis in Human Neuronal Cells: Protection by the Antioxidant N-acetylcysteine and the Genes bcl-2 and crmA," <i>Mol. Cell. Biol.</i> 15:2359-2366 (1995). | |
|-------|---|--|
| | erai et al., "Apoptosis as a Mechanism of Cell Death in Cultured T-lymphoblasts Acutely Infected with HIV-1," <i>J. lin. Invest.</i> , 87:1710-1715 (1991). | |
| | etzlaff et al., "Changes in Cytoskeletal Proteins in the Rat Facial Nucleus Following Axotomy," <i>J. Neurosci.</i> :3181-3189 (1988). | |
| | owfighi et al., "Is Werdnig-Hoffman Disease a Pure Lower Motor Neuron Disorder?," Acta Neuropathol. 65:270-80 (1985). | |
| | urner et al., "Ribozymes: Their Design and Use in Cancer," in Cancer Gene Therapy: Past Achievements and uture Challenges, Habib ed., Kluwer Academic/Plenum Publishers, New York, 2000. | |
| V | ossbeck et al., "Direct Transforming Activity of TGF-beta on Rat Fibroblasts," Int. J. Cancer 61:92-97 (1995). | |
| | Valkinshaw et al., "Induction of Apoptosis in Catecholaminergic PC12 Cells by L-DOPA. Implications for the reatment of Parkinson's Disease," J. Clin. Invest. 95:2458-2464 (1995). | |
| | Vestendorp et al., "Sensitization of T Cells to CD95-mediated Apoptosis by HIV-1 Tat And gp120," Nature 75:497-500 (1995). | |
| w | /hite et al., "Genetic Control of Programmed Cell Death In Drosophila," Science 264:677-683 (1994). | |
| W | /illiams et al., "Apoptosis: Final Control Point in Cell Biology," Trends Cell Biol. 2:263-267 (1992). | |
| w | /yllie, "Apoptosis. Death Gets A Brake," Nature 369:272-273 (1994). | |
| | u et al., "Elevation Of Neuronal Expression Of NAIP Reduces Ischemic Damage In The Rat Hippocampus," Nat. fed. 3:997-1004 (1997). | |
| | u et al., "Distribution Of Neuronal Apoptosis Inhibitory Protein-Like Immunoreactivity in the Rat Central Nervous ystem," <i>J. Comp. Neurol.</i> 382:247-259 (1997). | |
| In | uker et al., "Algorithms and Thermodynamics for RNA Secondary Structure Prediction: A Practical Guide," In RNA Biochemistry and Biotechnology, J. Barciszewski & B.F.C. Clark, eds., NATO ASI Series, Kluwer cademic Publishers, (1999). | |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
| | <u> </u> |